Circassia appoints new head to its Board of directors
pharmafile | December 6, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Circassia
Speciality biopharma firm Circassia has announced the appointment of Dr Jean-Jacques Garaud to its Board of directors.
Garaud has extensive pharmaceutical development experience having held a number of senior roles in the US and Europe, and was until recently the global head of Pharma Research and Early Development at F Hoffmann-La Roche.
“It is a great pleasure to welcome Dr Garaud to Circassia at this exciting time of transformation for the company,” said Sir Richard Sykes, Circassia’s chairman.
Commenting on his appointment, Garaud said: “I have been greatly impressed with the clinical results Circassia has achieved with its novel allergy treatments, and by the quality of the company’s development work. I look forward to contributing to the company’s success as it progresses its first product to market.”
Garaud has over 25 years’ experience of pharmaceutical R&D having worked for significant periods in both the US and Europe. He began his industry career as a clinical research physician, and went on to hold positions of increasing seniority at Rhone-Poulenc Rorer and Schering-Plough, where he became executive VP of Worldwide Clinical Research.
He subsequently held a number of roles at Novartis, including global head of Clinical Research and Development. On moving to F Hoffmann-La Roche, Garaud became global head of Pharmaceutical Development and chief medical officer.
Related Content

Circassia terminates AstraZeneca partnership in exchange for £150m debt settlement
Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with …

Circassia stumbles with allergy treatments at clinical trial stage, again
Circassia has slumped at the Phase 2 clinical trial stage again, after its failure with …
Circassia raises funds to develop allergy products
UK biopharma company Circassia has raised £60 million funding for the final stage of development …






